文献速递免疫规划

VSV-EBOV埃博拉疫苗诱导循环miRNA的动态变化

Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV.
PubMed 文献 · Vaccine · 2018-09-21

在WHO主导的VEBCON联盟I期试验中,研究者用RT-qPCR检测健康受种者接种VSV-EBOV后第0、1、3天血浆循环miRNA表达,发现hsa-miR-146a、hsa-miR-126、hsa-miR-199a、hsa-miR-484与适应性免疫应答强关联且预后表现良好,提示miRNA可能作为疫苗免疫原性预测的生物标志物。

要点

  • VSV-EBOV免疫后第0、1、3天血浆c-miRNA表达谱被系统检测。
  • hsa-miR-146a、hsa-miR-126、hsa-miR-199a、hsa-miR-484与适应性免疫应答强关联。
  • 上述miRNA展现良好预后性能并参与免疫相关功能。

核心结论

  • 结果提供证据表明miRNA可能作为预测疫苗诱导免疫原性的有用生物标志物。
  • 独特数据集为VSV-EBOV介导的保护性免疫应答分子机制提供见解,可能有助于解析免疫特征并加速策略性疫苗设计或个体化方案。

研究设计与样本

  • 作为WHO主导的VEBCON联盟的一部分,在I期试验中研究VSV-EBOV的安全性与免疫原性。
  • 使用RT-qPCR检测健康受种者接种VSV-EBOV后第0、1、3天血浆样本的循环miRNA表达水平,并进行计算机模拟分析评估潜在生物学相关性。
  • 将miRNA表达动态与先前报告的疫苗诱导抗体和细胞因子应答数据相关联,并通过生成ROC曲线评估预后能力。

主要发现

  • 鉴定出四个有前景的miRNA(hsa-miR-146a、hsa-miR-126、hsa-miR-199a、hsa-miR-484),与适应性免疫应答强关联,展现良好预后性能并涉及免疫相关功能。
  • 原文未报告具体表达倍数变化、ROC曲线下面积、置信区间或P值。

关键数值与推荐

  • 原文未报告诊断或预后阈值、推荐等级或具体效应量数值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

VSV-EBOV is a replication-competent Ebola virus (EBOV) vaccine, which was tested in clinical trials as response to the Ebola virus disease (EVD) outbreak 2013-2016. It is the most advanced EBOV candidate currently in the licensure process. The experimental vaccine was again administered as response to outbreaks in the Democratic Republic of Congo. However, underlying molecular mechanisms that convey protection remain incompletely understood. MicroRNAs (miRNAs) are known key regulators that influence gene expression on a post-transcriptional level. The miRNA-mediated control has emerged as a critical regulatory principle in the immune system, which strongly influences the balance of innate and adaptive immune responses by modulation of signaling pathways critical for differentiation of immune cells. We investigated expression levels of circulating miRNAs (c-miRNAs) in plasma from healthy vaccinees, as they may reflect cellular dynamics following VSV-EBOV immunization and additionally may serve as potential biomarkers for vaccine efficacy. As part of the WHO-led VEBCON consortium, we investigated safety and immunogenicity of VSV-EBOV in a phase I trial. A comprehensive analysis of expression levels on c-miRNAs from plasma samples following VSV-EBOV immunization (day 0, 1, 3 post vaccination) was conducted using RT-qPCR assays. Potential biological relevance was assessed using in silico analyses. Additionally, we correlated dynamics of miRNA expressions with our previously reported data on vaccine-induced antibody and cytokine responses and finally evaluated the prognostic power by generating ROC curves. We identified four promising miRNAs (hsa-miR-146a, hsa-miR-126, hsa-miR-199a, hsa-miR-484), showing a strong association with adaptive immune responses, exhibited favourable prognostic performance and are implicated in immunology-related functions. Our results provide evidence that miRNAs may serve as useful biomarkers for prediction of vaccine-induced immunogenicity. Furthermore, our unique data set provides insight into molecular mechanisms that underlie VSV-EBOV-mediated protective immune responses, which may help to decipher VSV-EBOV immune signature and accelerate strategic vaccine design or personalized approaches.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fischer T, Spohn M, Olearo F, et al. Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV. Vaccine. 2018. PMID: 30244872. doi:10.1016/j.vaccine.2018.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。